In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1859 News Items found
Pediatric oncologist Nai-Kong Cheung
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.
Memorial Sloan Kettering developmental biologist Luis Parada
Decoding the Biology of Brain Tumors

Brain cancer is deadly because it’s so difficult to study. Scientist Luis Parada has developed an innovative model to analyze how brain tumors form and respond to treatment.
Fiona and Stanley Druckenmiller
Donors on a Mission to Fast-Track Cancer Therapies at MSK

Meet Fiona and Stanley Druckenmiller, whose latest venture supports promising new avenues of research for experts at Memorial Sloan Kettering Cancer Center.
Luis Alberto Diaz Jr.
Luis Diaz’s Vision: Treating Cancer Earlier — Even Before It Develops

Luis Alberto Diaz, Jr. has dedicated his life’s work to addressing some of the most pressing challenges in cancer research — driven by one clear aim.
SKI immunologist Justin Perry holding a fish
Meet Justin Perry, a “Card-Carrying Alaskan” Whose Love for Science Took Him on an Unexpected Journey

Read an interview with Sloan Kettering Institute immunologist Justin Perry.
Stacia Smart and Owen Strong
Owen and Stacia: A Love Story

Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.
Sam Frackowiak, part of the Radiochemistry and Molecular Imaging Probe Core Facility, operates a robotic arm to prepare a radioactive theranostic drug that will seek out and destroy cancer cells.
Theranostics: A Smart Bomb for Cancer

When Dave Norkin was diagnosed at 39 with a rare cancer, he was told he had just months to live. Now, a decade later, he’s surviving — thanks to the emerging field of theranostics, which combines imaging and therapy for a search-and-destroy mission.
Craig B. Thompson, President and Chief Executive Officer of Memorial Sloan Kettering
To Our MSK Community

A generous gift provides a major boost to translational research at MSK.
Photo of a man, woman, and child sitting outside smiling
Translating Science Into Cures: Bringing Fresh Hope to the Denisiuk Family

Mark Denisiuk was diagnosed with acute myeloid leukemia in the spring of 2021. He found hope when he enrolled in an early trial of an entirely new kind of drug that’s based on lab research conducted at MSK.
Memorial Sloan Kettering patient Rebecca Lerner smiling in the hospital
Unlocking a Mystery: What’s Behind the Rise In Colorectal Cancer Among Young People

Doctors and scientists at MSK are desperately trying to figure out why more young patients like Rebecca, 33, are getting colorectal cancer — and how best to treat them.